These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10898675)

  • 21. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system.
    Drusano GL; Bilello PA; Symonds WT; Stein DS; McDowell J; Bye A; Bilello JA
    Antimicrob Agents Chemother; 2002 Feb; 46(2):464-70. PubMed ID: 11796359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
    McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
    HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
    Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
    Capparelli EV; Letendre SL; Ellis RJ; Patel P; Holland D; McCutchan JA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2504-6. PubMed ID: 15917556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
    Archary M; Mcllleron H; Bobat R; LaRussa P; Sibaya T; Wiesner L; Hennig S
    Br J Clin Pharmacol; 2019 Sep; 85(9):2066-2075. PubMed ID: 31141195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
    Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
    J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of abacavir in infants, toddlers and children.
    Zhao W; Piana C; Danhof M; Burger D; Della Pasqua O; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2013 Jun; 75(6):1525-35. PubMed ID: 23126277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the pharmacokinetics of abacavir.
    Yuen GJ; Weller S; Pakes GE
    Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence of abacavir generic and innovator formulations under fasting and fed conditions.
    Marier JF; Borges M; Plante G; Dimarco M; Morelli G; Tippabhotla SK; Vijan T; Singla AK; Garg M; Monif T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):284-91. PubMed ID: 16800101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.
    Izzedine H; Launay-Vacher V; Aymard G; Legrand M; Deray G
    Nephron; 2001 Sep; 89(1):62-7. PubMed ID: 11528234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.